Alzheimer's disease can be accurately diagnosed using a new brain imaging method which can reveal the spread of tau protein depositions, which is linked to Alzheimer's cases.

TOP INSIGHT
Alzheimer's disease can be correctly diagnosed using a new brain imaging technique which can show the spread of particular tau protein depositions associated with Alzheimer's cases.
There are two proteins that are known to be linked to Alzheimer's disease - beta-amyloid, which forms what is known as plaque in the brain, and tau, which forms tangles within the brain cells. Beta-amyloid spreads throughout the brain at an early stage, decades before the patient notices signs of the disease. Tau, on the other hand, starts to spread at a later stage, from the temporal lobes to other parts of the brain.
"It is when tau begins to spread that the neurons start dying and the patient experiences the first problems with the disease. If we scan a patient with memory difficulties and he or she proves to have a lot of tau in the brain, we know with a high degree of certainty that it is a case of Alzheimer's", says senior researcher Rik Ossenkoppele, Lund University and Amsterdam University Medical Center.
The article presents a study of over 700 patients. Besides Lund-Malmö in southern Sweden, researchers from San Francisco and Seoul took part in the study, and the patients were diagnosed in memory clinics from these regions.
The presence of tau in the brain was revealed by a PET scanner, a medical imaging technology which uses radioactive markers that make their way to different areas in the body.
The international study showed that the new tau-PET method had both great sensitivity and specificity: it detected 90-95 percent of all cases of Alzheimer's and gave only a few false positive results in patients with other diseases. The tau-PET method had clearly superior diagnostic accuracy compared to MRI, and fewer false-positive results than a beta-amyloid PET, two methods that are routinely used today. Tau-PET should, therefore, be of great use in the investigation of patients with memory problems, as soon as the method is approved for clinical use.
Although there is currently no cure for Alzheimer's, it is still important for patients to receive the correct diagnosis. On the one hand, the patient can be given symptom-relieving medication, and on the other, physical activity, a good diet and a correct dosage of the patient's other medication can optimize cognitive ability. The tau-PET method could also be valuable in trials of new medication against Alzheimer's, as it can show whether new drugs have succeeded in preventing the spread of tau in the brain.
Source-Eurekalert
MEDINDIA




Email










